Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Three-times Weekly Dosing of GSK1278863 in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease Who Are Switched From a Stable Dose of an Erythropoiesis-stimulating Agent [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating three-times weekly dosing of GSK1278863 in hemodialysis patients with anemia due to chronic kidney disease; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Chronic Kidney Disease

Drugs mentioned

• GSK1278863

Snippet

Sponsor: GlaxoSmithKline | Conditions: Anaemia | Phase 2 | Status: COMPLETED | Results posted: 2018-05-21